Kura Oncology Inc (KURA)
Healthcare
Biotechnology
9.20 $
+2.0%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns Kura Oncology Inc (KURA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 79.3% of the shares are freely tradable; institutional investors hold 96.4%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
96.4%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.4%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
79.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
15.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
89Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 10.86 | 9,637,531 | +7.0 | 03/31/2026 |
| Suvretta Capital Management, LLC | 9.66 | 8,575,422 | +0.0 | 03/31/2026 |
| Bvf Inc | 9.51 | 8,445,769 | -2.0 | 03/31/2026 |
| State Street Corp | 5.08 | 4,511,891 | -8.5 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.26 | 3,785,685 | +0.0 | 03/31/2026 |
| Armistice Capital, LLC | 4.21 | 3,736,000 | -24.3 | 03/31/2026 |
| Prosight Management, LP | 3.78 | 3,356,700 | +32.7 | 03/31/2026 |
| Deep Track Capital, LP | 2.98 | 2,643,542 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.42 | 3,033,476 | -0.3 | 07/28/2026 |
| Vanguard Morn Total Stk Mkt Idx Investor | 3.15 | 2,799,338 | +6.3 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.